Suppr超能文献

血浆肾素活性和去甲肾上腺素作为硝苯地平和卡托普利降压效果的预测指标。

Plasma renin activity and norepinephrine as predictors for antihypertensive effects of nifedipine and captopril.

作者信息

Kusaka M, Atarashi K, Matsumoto K, Sumida Y, Matsuura H, Shingu T, Kajiyama G

机构信息

Saiseikai Hiroshima Hospital, 1st Department of Internal Medicine, Hiroshima University, Japan.

出版信息

Am J Hypertens. 1991 Sep;4(9):735-9. doi: 10.1093/ajh/4.9.735.

Abstract

To examine predictors for the efficacy of antihypertensive agents, we investigated the effects of nifedipine and captopril on blood pressure (BP) and humoral factors in patients with essential hypertension. Eleven essential hypertensive patients (mean age: 54) were treated with long acting nifedipine at 20 to 40 mg/day for 8 weeks and 25 essential hypertensives (mean age: 51) were treated with captopril at 37.5 to 75 mg/day. Blood pressure was measured every 2 weeks. Plasma renin activity (PRA), and plasma concentrations of aldosterone, epinephrine and norepinephrine were determined before and at the end of treatment. Both nifedipine and captopril decreased BP (nifedipine: mean BP 119 +/- 3 to 101 +/- 2 mm Hg, captopril: 124 +/- 2 to 100 +/- 2, P less than .01 for each), whereas neither of them affected heart rate. The 8-week treatment of nifedipine showed no significant effect on humoral factors. Captopril increased PRA by 63% (P less than .05) and decreased plasma epinephrine by 42% (P less than .01) and norepinephrine by 35% (P less than .01). The change in mean BP was positively correlated with pretreatment PRA (r = 0.68, P less than .01) in nifedipine-treated patients and inversely with pretreatment norepinephrine (r = -0.53, P less than .01) in captopril treatment. The results suggest that both nifedipine and captopril were effective antihypertensive agents and that the long term treatment of nifedipine is more effective in essential hypertensives with lower PRA, while captopril is more effective in those with higher plasma norepinephrine concentration.

摘要

为研究抗高血压药物疗效的预测因素,我们调查了硝苯地平和卡托普利对原发性高血压患者血压(BP)及体液因子的影响。11例原发性高血压患者(平均年龄:54岁)接受长效硝苯地平治疗,剂量为每日20至40毫克,疗程8周;25例原发性高血压患者(平均年龄:51岁)接受卡托普利治疗,剂量为每日37.5至75毫克。每2周测量一次血压。在治疗前及治疗结束时测定血浆肾素活性(PRA)、醛固酮、肾上腺素及去甲肾上腺素的血浆浓度。硝苯地平和卡托普利均能降低血压(硝苯地平:平均血压从119±3降至101±2毫米汞柱,卡托普利:从124±2降至100±2,两者P均小于0.01),但两者均不影响心率。硝苯地平8周治疗对体液因子无显著影响。卡托普利使PRA升高63%(P小于0.05),使血浆肾上腺素降低42%(P小于0.01),去甲肾上腺素降低35%(P小于0.01)。硝苯地平治疗患者平均血压的变化与治疗前PRA呈正相关(r = 0.68,P小于0.01),卡托普利治疗患者平均血压的变化与治疗前去甲肾上腺素呈负相关(r = -0.53,P小于0.01)。结果表明,硝苯地平和卡托普利均为有效的抗高血压药物,硝苯地平长期治疗对PRA较低的原发性高血压患者更有效,而卡托普利对血浆去甲肾上腺素浓度较高的患者更有效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验